Homes
Public Notices
News
Local news
Editor’s Pick
Pittsburgh
Local Government
My American Story
Roads, Travel and Traffic
Regional
U.S. and World
Business
Sports
HS Sports
College Sports
Penguins
Pirates
Steelers
Athlete of the Week
Wild Things
Pony Baseball
Outdoors
Columns
Opinion
Columns
Editorials
Letters to the Editor
Op Eds
Living
Neighbors
School News
Entertainment
Home and Garden
Food
Police Beat
Obituaries
Classifieds
Legal Notices
Jobs
Sponsored Content
e-Edition
close
Washington County
Greene County
Mon Valley
News
Local news
Police Beat
Pittsburgh
Local Government
Roads, Travel and Traffic
Helping The Helpers
My American Story
Regional
U.S. and World
Business News
Sports
High School Sports
College Sports
Penguins
Pirates
Steelers
Wild Things
Pro Sports
Outdoors
Sports Column
Obituaries
Opinion
Columns
Editorials
Letters to the Editor
Op-Ed
Living
Neighbors
Health and Wellness
Entertainment
Home and Garden
Classifieds
Jobs
Contact Us
Advertise With Us
Customer Service
Contact Information
Submission Forms
Statement of Values
Misc
Special Sections
Events
Sponsored Content
Newsletter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude+Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Glaukos Corporation Common Stock
(NY:
GKOS
)
121.69
+8.05 (+7.08%)
Official Closing Price
Updated: 7:00 PM EDT, Jun 4, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Glaukos Corporation Common Stock
< Previous
1
2
...
4
5
6
7
8
9
10
11
Next >
Glaukos Comments on the Centers for Medicare and Medicaid Services 2022 Proposed Physician Fee Schedule
July 14, 2021
From
Glaukos Corporation
Via
Business Wire
Glaukos Stock Sees Its Relative Strength Rating Improve To Key Above-80 Level
↗
July 01, 2021
Glaukos stock had its Relative Strength (RS) Rating upgraded from 78 to 81 Thursday. Is Glaukos on your watchlist?
Via
Investor's Business Daily
Glaukos Achieves Pipeline Milestone with Completion of Patient Enrollment in U.S. NDA Phase 3 Clinical Trials for iDose® TR
June 10, 2021
From
Glaukos Corporation
Via
Business Wire
Glaukos Announces Australia’s TGA Regulatory Approval for PRESERFLO™ MicroShunt
June 08, 2021
From
Glaukos
Via
Business Wire
Glaukos's Earnings: A Preview
↗
May 04, 2021
Glaukos (NYSE:GKOS) announces its next round of earnings this Wednesday, May 05. Here is Benzinga's look at Glaukos's Q1 earnings report. Net Income, Earnings, And Earnings Per...
Via
Benzinga
Week Ahead In Biotech (May 2-8): ChemoCentryx Adcom, Ophthalmology Conference Presentations, Earnings Deluge
↗
May 01, 2021
Biopharma stocks experienced volatility in the week ended April 30, as stocks reacted to earnings, data readouts and a handful of FDA decisions. Earnings prints from big name...
Via
Benzinga
Glaukos Announces Participation in the William Blair 41st Annual Growth Stock Conference
May 19, 2021
From
Glaukos Corporation
Via
Business Wire
Glaukos Expands its PRESERFLO™ MicroShunt Relationship with Santen via New License Agreement
May 18, 2021
From
Glaukos Corporation
Via
Business Wire
Glaukos Corp (GKOS) Q1 2021 Earnings Call Transcript
↗
May 05, 2021
GKOS earnings call for the period ending March 31, 2021.
Via
The Motley Fool
Topics
Earnings
Glaukos Corporation Announces First Quarter 2021 Financial Results
May 05, 2021
From
Glaukos Corporation
Via
Business Wire
Why Glaukos's Stock is Up During Today's Session
↗
April 08, 2021
Glaukos's Stock Price And Volume Action Glaukos (NYSE:GKOS) is curre...
Via
Benzinga
The Daily Biotech Pulse: Athenex, NeoGenomics And Amryt In M&A Mix, European Nod For Roche's Cancer Immunotherapy, Earnings Deluge Continues
↗
May 05, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 4) AbbVie Inc. (NYSE: ABBV)...
Via
Benzinga
Glaukos Announces the Release of its 2020 Sustainability Report
April 27, 2021
From
Glaukos Corporation
Via
Business Wire
The Daily Biotech Pulse: KemPharm Receives $10M Milestone Payment, Zymergen, Neuropace Debut On Nasdaq, Renalytix Wins US Government Contract, 2 IPOs
↗
April 22, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 21) Alexion Pharmaceuticals,...
Via
Benzinga
Glaukos Announces Global Licensing Agreement Amendment with Intratus, Inc. to Include the Treatment of Presbyopia
April 22, 2021
From
Glaukos Corporation
Via
Business Wire
Glaukos Corporation to Release First Quarter 2021 Financial Results after Market Close on May 5
April 14, 2021
From
Glaukos Corporation
Via
Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For April 8, 2021
↗
April 08, 2021
Upgrades According to Oppenheimer, the prior rating for Glaukos Corp (NYSE:GKOS) was changed from Perform to Outperform. Glaukos earned $0.02 in the fourth quarter,...
Via
Benzinga
< Previous
1
2
...
4
5
6
7
8
9
10
11
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
Starting at $3.75
/
week.
Subscribe Today